| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Lipigon Pharmaceuticals AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.015 |
| 52 Week High | kr0.06 |
| 52 Week Low | kr0.0086 |
| Beta | 0.37 |
| 1 Month Change | 56.12% |
| 3 Month Change | -35.17% |
| 1 Year Change | -46.88% |
| 3 Year Change | -97.99% |
| 5 Year Change | n/a |
| Change since IPO | -98.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9RP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 75.9% | 0.5% | -0.3% |
| 1Y | -46.9% | -25.8% | 4.5% |
Return vs Industry: 9RP underperformed the German Biotechs industry which returned -25.8% over the past year.
Return vs Market: 9RP underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 9RP volatility | |
|---|---|
| 9RP Average Weekly Movement | 55.0% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9RP's share price has been volatile over the past 3 months.
Volatility Over Time: 9RP's weekly volatility has increased from 49% to 55% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6 | Stefan Nilsson | www.lipigon.se |
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia.
Lipigon Pharmaceuticals AB (publ) Fundamentals Summary
| 9RP fundamental statistics | |
|---|---|
| Market cap | €3.50m |
| Earnings (TTM) | -€1.05m |
| Revenue (TTM) | €1.42m |
2.5x
P/S Ratio-3.3x
P/E RatioIs 9RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9RP income statement (TTM) | |
|---|---|
| Revenue | kr16.41m |
| Cost of Revenue | kr21.52m |
| Gross Profit | -kr5.12m |
| Other Expenses | kr7.01m |
| Earnings | -kr12.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | -31.19% |
| Net Profit Margin | -73.92% |
| Debt/Equity Ratio | 0% |
How did 9RP perform over the long term?
See historical performance and comparison